Genmab A/S

    Jurisdiction
    Denmark
    LEI
    529900MTJPDPE4MHJ122
    ISIN
    DK0010272202 (GMAB.CO)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    50 / 100
    Even with peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    €297.30 8.5% undervalued
    Financial strength (Piotroski F-Value)
    5 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    4 / 7

    Profile

    Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. Read full profile

    Fundamentals

    Net revenue
    €3.05B
    Gross margin
    95.0%
    EBIT
    €1.05B
    EBIT margin
    34.4%
    Net income
    €997.43M
    Net margin
    32.7%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €3.60B +17.8% €948.80M -4.9%
    €4.12B +14.6% €1.17B +23.1%
    €5.08B +23.2% €1.64B +40.7%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    No insider transactions in the last 90 days. View older insider transactions

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 2.3M $44.30M +336K Buy

    Earnings Calls

    Latest earnings call: August 7, 2025 (Q2 2025)

    Add to watchlist

    Notifications